Ascletis Pharma
Ascletis is a Hangzhou biotech listed in Hong Kong, first known for hepatitis C antivirals, which sponsors phase 3 cancer trials among its liver-disease and metabolic programmes.
Overview
Ascletis Pharma, headquartered in Hangzhou and listed in Hong Kong, began with direct-acting antivirals for hepatitis C in China and has since moved into liver disease, metabolic disease and oncology, including a PD-L1 antibody programme. ClinicalTrials.gov lists Ascletis as lead sponsor of a phase 3 cancer trial.
Similar pages
not linked directly; found by shared links- CompanyCan-Fite BioPharma
Shares Pivotal (registrational) trial, Clinical trial, Hepatocellular carcinoma and the tag ctgov-sponsor.
- CompanyGC Cell
Shares Pivotal (registrational) trial, Clinical trial, Hepatocellular carcinoma and the tag ctgov-sponsor.
- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEurofarma
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyGrifols
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.